Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis

Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitatio...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2021, Vol.2021, p.6548479-6
Main Authors: He, Xuni, Dai, Zhuhua, Shi, Peina, Hong, Jiemin
Format: Article
Language:English
Subjects:
Bleeding
Blood pressure
Blood transfusions
Cirrhosis
Disease
Drug dosages
Erythrocytes
Esophagus
Evidence-based medicine
Fibrinogen
Gastroenterology
Heart rate
Hematemesis
Hematocrit
Hemoglobin
Hepatitis
Intravenous administration
Liver
Liver cirrhosis
Mortality
Patients
Platelets
Somatostatin
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3
cites cdi_FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3
container_end_page 6
container_issue
container_start_page 6548479
container_title Evidence-based complementary and alternative medicine
container_volume 2021
creator He, Xuni
Dai, Zhuhua
Shi, Peina
Hong, Jiemin
description Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitation in the treatment of upper gastrointestinal bleeding in the patients with liver cirrhosis. Methods. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. They were randomly assigned into the study group (n = 42) and control group (n = 42). All patients were given intravenous drip of somatostatin. The study group was supplemented with restricted fluid resuscitation therapy. The hemoglobin (Hb), platelet, fibrinogen, hematocrit, transfusion volume of red blood cells, hemostatic time, hemostatic rates in 0 h–24 h, 24 h–48 h, and >48 h, rebleeding rates, resuscitation rate, and incidence rates of complications were compared between the two groups 48 h after treatment. Results. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group 48 h after treatment P
doi_str_mv 10.1155/2021/6548479
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8550838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2589610768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3</originalsourceid><addsrcrecordid>eNp9kcFvFCEUxomxsbV682xIvDSxa4GBgbk0satbm2yi0TbxRmCG6dKwMAKzm_4h_r8y2XWjHjwBj9_78t73AfAKo3cYM3ZBEMEXNaOC8uYJOMGc4hklQjw93Pn3Y_A8pQeESMM5fwaOK8oJrik6AT9vfI5qY3wYE_wQ7QBDD7-FtcohZZWth4vgXNiaDupH-NWkHG2by2vhRttNhTG1diKDhznA22hUhnfDYCK8VoUO1ufSZb1y8MoZ01l_D4vsl9JifE5wa_MKLu2mNMxtjKuQbHoBjnrlknm5P0_B3eLj7fzTbPn5-mb-fjlrKRV5Rg2piK6xwaTXWLOGclwJVMq617pnPamFaCqCqNZNrXFVcc1YjRHiSHRUV6fgcqc7jHptutZMZjg5RLtW8VEGZeXfP96u5H3YSMEYEpUoAmd7gRh-jGVPubapNc4pb4qjkrAGEyIa1hT0zT_oQxhjsWWiRFOm4vUkeL6j2hhSiqY_DIORnPKWU95yn3fBX_-5wAH-HXAB3u6AlfWd2tr_y_0CCc-1WA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2589610768</pqid></control><display><type>article</type><title>Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis</title><source>Publicly Available Content Database</source><source>Wiley Open Access</source><creator>He, Xuni ; Dai, Zhuhua ; Shi, Peina ; Hong, Jiemin</creator><contributor>Tan, Songwen ; Songwen Tan</contributor><creatorcontrib>He, Xuni ; Dai, Zhuhua ; Shi, Peina ; Hong, Jiemin ; Tan, Songwen ; Songwen Tan</creatorcontrib><description><![CDATA[Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitation in the treatment of upper gastrointestinal bleeding in the patients with liver cirrhosis. Methods. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. They were randomly assigned into the study group (n = 42) and control group (n = 42). All patients were given intravenous drip of somatostatin. The study group was supplemented with restricted fluid resuscitation therapy. The hemoglobin (Hb), platelet, fibrinogen, hematocrit, transfusion volume of red blood cells, hemostatic time, hemostatic rates in 0 h–24 h, 24 h–48 h, and >48 h, rebleeding rates, resuscitation rate, and incidence rates of complications were compared between the two groups 48 h after treatment. Results. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group 48 h after treatment P<0.01. The proportion of patients with excellent response was notably higher in the study group than in the control group P<0.05. The overall response rate of the study group was 90.48%, which was significantly higher than 71.43% in the control group P<0.05. The study group had lower transfusion volume of red blood cells, shorter hemostatic time, and lower rebleeding rates than the control group P<0.01. The hemostatic rate of 0 h–24 h in the study group was remarkably higher than that in the control group P<0.05. The hemostatic rate of >48 h in the study group was lower than that in the control group P<0.05. The overall incidence rate of complications in the study group was 9.52%, which was significantly lower than 30.95% in the control group P<0.05. Conclusion. These data suggest that intravenous drip of somatostatin followed by restricted fluid resuscitation leads to a better clinical efficacy in treating upper gastrointestinal bleeding in patients with liver cirrhosis considering higher resuscitation rate and hemostatic rate and reduced incidence of complications, which is conducive to the recovery of patients and worthy of further clinical promotion.]]></description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2021/6548479</identifier><identifier>PMID: 34721640</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Bleeding ; Blood pressure ; Blood transfusions ; Cirrhosis ; Disease ; Drug dosages ; Erythrocytes ; Esophagus ; Evidence-based medicine ; Fibrinogen ; Gastroenterology ; Heart rate ; Hematemesis ; Hematocrit ; Hemoglobin ; Hepatitis ; Intravenous administration ; Liver ; Liver cirrhosis ; Mortality ; Patients ; Platelets ; Somatostatin ; Ultrasonic imaging</subject><ispartof>Evidence-based complementary and alternative medicine, 2021, Vol.2021, p.6548479-6</ispartof><rights>Copyright © 2021 Xuni He et al.</rights><rights>Copyright © 2021 Xuni He et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Xuni He et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3</citedby><cites>FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3</cites><orcidid>0000-0002-4853-6336</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2589610768/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2589610768?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,4010,25731,27900,27901,27902,36989,36990,44566,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34721640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tan, Songwen</contributor><contributor>Songwen Tan</contributor><creatorcontrib>He, Xuni</creatorcontrib><creatorcontrib>Dai, Zhuhua</creatorcontrib><creatorcontrib>Shi, Peina</creatorcontrib><creatorcontrib>Hong, Jiemin</creatorcontrib><title>Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description><![CDATA[Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitation in the treatment of upper gastrointestinal bleeding in the patients with liver cirrhosis. Methods. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. They were randomly assigned into the study group (n = 42) and control group (n = 42). All patients were given intravenous drip of somatostatin. The study group was supplemented with restricted fluid resuscitation therapy. The hemoglobin (Hb), platelet, fibrinogen, hematocrit, transfusion volume of red blood cells, hemostatic time, hemostatic rates in 0 h–24 h, 24 h–48 h, and >48 h, rebleeding rates, resuscitation rate, and incidence rates of complications were compared between the two groups 48 h after treatment. Results. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group 48 h after treatment P<0.01. The proportion of patients with excellent response was notably higher in the study group than in the control group P<0.05. The overall response rate of the study group was 90.48%, which was significantly higher than 71.43% in the control group P<0.05. The study group had lower transfusion volume of red blood cells, shorter hemostatic time, and lower rebleeding rates than the control group P<0.01. The hemostatic rate of 0 h–24 h in the study group was remarkably higher than that in the control group P<0.05. The hemostatic rate of >48 h in the study group was lower than that in the control group P<0.05. The overall incidence rate of complications in the study group was 9.52%, which was significantly lower than 30.95% in the control group P<0.05. Conclusion. These data suggest that intravenous drip of somatostatin followed by restricted fluid resuscitation leads to a better clinical efficacy in treating upper gastrointestinal bleeding in patients with liver cirrhosis considering higher resuscitation rate and hemostatic rate and reduced incidence of complications, which is conducive to the recovery of patients and worthy of further clinical promotion.]]></description><subject>Bleeding</subject><subject>Blood pressure</subject><subject>Blood transfusions</subject><subject>Cirrhosis</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Erythrocytes</subject><subject>Esophagus</subject><subject>Evidence-based medicine</subject><subject>Fibrinogen</subject><subject>Gastroenterology</subject><subject>Heart rate</subject><subject>Hematemesis</subject><subject>Hematocrit</subject><subject>Hemoglobin</subject><subject>Hepatitis</subject><subject>Intravenous administration</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Platelets</subject><subject>Somatostatin</subject><subject>Ultrasonic imaging</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kcFvFCEUxomxsbV682xIvDSxa4GBgbk0satbm2yi0TbxRmCG6dKwMAKzm_4h_r8y2XWjHjwBj9_78t73AfAKo3cYM3ZBEMEXNaOC8uYJOMGc4hklQjw93Pn3Y_A8pQeESMM5fwaOK8oJrik6AT9vfI5qY3wYE_wQ7QBDD7-FtcohZZWth4vgXNiaDupH-NWkHG2by2vhRttNhTG1diKDhznA22hUhnfDYCK8VoUO1ufSZb1y8MoZ01l_D4vsl9JifE5wa_MKLu2mNMxtjKuQbHoBjnrlknm5P0_B3eLj7fzTbPn5-mb-fjlrKRV5Rg2piK6xwaTXWLOGclwJVMq617pnPamFaCqCqNZNrXFVcc1YjRHiSHRUV6fgcqc7jHptutZMZjg5RLtW8VEGZeXfP96u5H3YSMEYEpUoAmd7gRh-jGVPubapNc4pb4qjkrAGEyIa1hT0zT_oQxhjsWWiRFOm4vUkeL6j2hhSiqY_DIORnPKWU95yn3fBX_-5wAH-HXAB3u6AlfWd2tr_y_0CCc-1WA</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>He, Xuni</creator><creator>Dai, Zhuhua</creator><creator>Shi, Peina</creator><creator>Hong, Jiemin</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4853-6336</orcidid></search><sort><creationdate>2021</creationdate><title>Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis</title><author>He, Xuni ; Dai, Zhuhua ; Shi, Peina ; Hong, Jiemin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bleeding</topic><topic>Blood pressure</topic><topic>Blood transfusions</topic><topic>Cirrhosis</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Erythrocytes</topic><topic>Esophagus</topic><topic>Evidence-based medicine</topic><topic>Fibrinogen</topic><topic>Gastroenterology</topic><topic>Heart rate</topic><topic>Hematemesis</topic><topic>Hematocrit</topic><topic>Hemoglobin</topic><topic>Hepatitis</topic><topic>Intravenous administration</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Platelets</topic><topic>Somatostatin</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Xuni</creatorcontrib><creatorcontrib>Dai, Zhuhua</creatorcontrib><creatorcontrib>Shi, Peina</creatorcontrib><creatorcontrib>Hong, Jiemin</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Xuni</au><au>Dai, Zhuhua</au><au>Shi, Peina</au><au>Hong, Jiemin</au><au>Tan, Songwen</au><au>Songwen Tan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>6548479</spage><epage>6</epage><pages>6548479-6</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract><![CDATA[Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitation in the treatment of upper gastrointestinal bleeding in the patients with liver cirrhosis. Methods. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. They were randomly assigned into the study group (n = 42) and control group (n = 42). All patients were given intravenous drip of somatostatin. The study group was supplemented with restricted fluid resuscitation therapy. The hemoglobin (Hb), platelet, fibrinogen, hematocrit, transfusion volume of red blood cells, hemostatic time, hemostatic rates in 0 h–24 h, 24 h–48 h, and >48 h, rebleeding rates, resuscitation rate, and incidence rates of complications were compared between the two groups 48 h after treatment. Results. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group 48 h after treatment P<0.01. The proportion of patients with excellent response was notably higher in the study group than in the control group P<0.05. The overall response rate of the study group was 90.48%, which was significantly higher than 71.43% in the control group P<0.05. The study group had lower transfusion volume of red blood cells, shorter hemostatic time, and lower rebleeding rates than the control group P<0.01. The hemostatic rate of 0 h–24 h in the study group was remarkably higher than that in the control group P<0.05. The hemostatic rate of >48 h in the study group was lower than that in the control group P<0.05. The overall incidence rate of complications in the study group was 9.52%, which was significantly lower than 30.95% in the control group P<0.05. Conclusion. These data suggest that intravenous drip of somatostatin followed by restricted fluid resuscitation leads to a better clinical efficacy in treating upper gastrointestinal bleeding in patients with liver cirrhosis considering higher resuscitation rate and hemostatic rate and reduced incidence of complications, which is conducive to the recovery of patients and worthy of further clinical promotion.]]></abstract><cop>United States</cop><pub>Hindawi</pub><pmid>34721640</pmid><doi>10.1155/2021/6548479</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4853-6336</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1741-427X
ispartof Evidence-based complementary and alternative medicine, 2021, Vol.2021, p.6548479-6
issn 1741-427X
1741-4288
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8550838
source Publicly Available Content Database; Wiley Open Access
subjects Bleeding
Blood pressure
Blood transfusions
Cirrhosis
Disease
Drug dosages
Erythrocytes
Esophagus
Evidence-based medicine
Fibrinogen
Gastroenterology
Heart rate
Hematemesis
Hematocrit
Hemoglobin
Hepatitis
Intravenous administration
Liver
Liver cirrhosis
Mortality
Patients
Platelets
Somatostatin
Ultrasonic imaging
title Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A11%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20Drip%20of%20Somatostatin%20Followed%20by%20Restricted%20Fluid%20Resuscitation%20to%20Treat%20Upper%20Gastrointestinal%20Bleeding%20in%20Patients%20with%20Liver%20Cirrhosis&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=He,%20Xuni&rft.date=2021&rft.volume=2021&rft.spage=6548479&rft.epage=6&rft.pages=6548479-6&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2021/6548479&rft_dat=%3Cproquest_pubme%3E2589610768%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-4e232b61e12fb1b594713804e2bfbbf5f268893204bb96b1337b556100708d4b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2589610768&rft_id=info:pmid/34721640&rfr_iscdi=true